Windlas Biotech Ltd

Windlas Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 September 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

With a decisive surge to Rs 1181 on 7 Sep 2026, Windlas Biotech Ltd has reached a fresh 52-week high, outperforming its sector and demonstrating robust momentum across multiple technical indicators.

With a decisive break above Rs 1150, Windlas Biotech Ltd has reached a new 52-week high on 4 Sep 2026, marking a significant milestone in its price momentum. This surge comes after a sustained four-day rally that has propelled the stock 14.48% higher, outpacing its sector and the broader market.

With a decisive break above Rs 1117.95 on 3 Sep 2026, Windlas Biotech Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Windlas Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid robust price appreciation. The pharmaceutical and biotechnology company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have risen, signalling a recalibration of investor expectations relative to historical and peer benchmarks.

The Sensex declined 0.71% on 02 Sep 2026, while Windlas Biotech Ltd surged 7.71%, outperforming its Pharmaceuticals & Biotechnology sector by over 8 percentage points. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, which also hit a new 52-week high of Rs 1093.05 during the day.

Surging past its previous peak, Windlas Biotech Ltd touched a fresh 52-week high of Rs 1093.05 on 2 Sep 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of broad technical alignment, underscoring the stock’s robust upward trajectory despite a subdued broader market.

Windlas Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 August 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

The Sensex declined by 0.47% on 19 Aug 2026, while Windlas Biotech Ltd surged 7.76%, reaching an intraday high of Rs 980. This 7.07 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally amid a broadly weak market environment.

Windlas Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Windlas Biotech Ltd has experienced a significant shift in price momentum, reflecting a transition from a mildly bullish to a bullish technical trend. This change is underpinned by a series of positive signals from key technical indicators including MACD, Bollinger Bands, and moving averages, signalling renewed investor confidence in the pharmaceuticals and biotechnology sector.

The Sensex declined 0.43% on 11 Aug 2026, while Windlas Biotech Ltd surged 8.29%, touching an intraday high of Rs 919. This 8.51-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally amid a broadly weak market backdrop.

Windlas Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 August 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Windlas Biotech Ltd has seen a notable change in its valuation parameters, moving from an attractive to a fair rating as of mid-2026. This shift reflects evolving market perceptions amid a competitive pharmaceuticals and biotechnology sector, where peers continue to command premium multiples. Investors are advised to consider these valuation dynamics alongside the company’s operational metrics and broader market trends.

Windlas Biotech Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 27 July 2026, providing investors with the latest insights into the company’s performance and outlook.